Chemotherapy Induced Neutropenia Treatment

Chemotherapy Induced Neutropenia Treatment Market Outlook

The global chemotherapy induced neutropenia treatment market is projected to reach approximately USD 2.3 billion by 2035, growing at a compound annual growth rate (CAGR) of about 6.5% during the forecast period from 2025 to 2035. This robust growth is driven by the increasing prevalence of cancer worldwide, alongside the rising adoption of chemotherapy protocols that significantly contribute to neutropenia cases. Additionally, advancements in targeted therapies and increased funding for cancer research are expected to enhance treatment options, thereby creating a conducive environment for market expansion. Increasing awareness about the importance of managing chemotherapy-induced side effects among healthcare providers and patients is further bolstering the market growth. The evolving landscape of personalized medicine and the integration of supportive care in oncology are also key factors that support the demand for effective treatment solutions for chemotherapy-induced neutropenia.

Growth Factor of the Market

The chemotherapy induced neutropenia treatment market is significantly influenced by a variety of growth factors. One major driver is the increasing number of cancer cases globally, which necessitates efficient management of treatment-related complications such as neutropenia. Furthermore, the development of novel therapies, including biosimilars and genetically engineered medications, has broadened the array of treatment options available to healthcare providers, making it easier to tailor approaches to individual patient needs. Additionally, the rise in healthcare expenditure and the growing focus on improving patient outcomes in oncology care are contributing to market growth. Advancements in diagnostics that allow for the early identification of neutropenia also play a crucial role, as they enable timely interventions that can mitigate the severity of the condition. Moreover, an increasing emphasis on preventive healthcare and supportive therapies is fostering a more integrated and holistic approach to cancer care, which is expected to positively impact the market dynamics.

Key Highlights of the Market

• Increasing incidence of cancer cases globally drives the demand for effective treatment options.
• Advancements in drug development, including novel therapies and biosimilars, expand market offerings.
• Growing awareness among healthcare professionals and patients regarding the management of chemotherapy side effects.
• Rising healthcare spending and focus on patient-centric care enhance market growth opportunities.
• Early diagnosis and proactive management of chemotherapy-induced neutropenia are gaining traction among oncologists.

By Treatment Type

Colony-Stimulating Factors:

Colony-Stimulating Factors (CSFs) are pivotal in the treatment of chemotherapy-induced neutropenia, as they play a crucial role in stimulating the production of white blood cells, particularly neutrophils. Filgrastim and Pegfilgrastim are the most commonly utilized CSFs that enhance neutrophil recovery post-chemotherapy. Their effectiveness in reducing the incidence of febrile neutropenia, a serious complication of chemotherapy, is well-documented and thus drives their demand in clinical settings. Besides, the use of CSFs can lead to shorter hospital stays and reduced costs associated with managing neutropenia complications. As more oncologists embrace these agents due to their benefits and the growing body of clinical evidence supporting their use, the segment is expected to witness significant growth.

Antibiotics:

Antibiotics are essential in the management of chemotherapy-induced neutropenia, primarily for the prevention and treatment of infections that patients may develop due to their compromised immune systems. Broad-spectrum antibiotics are typically prescribed to address the high risk of febrile neutropenia, ensuring that bacterial infections are swiftly managed. The increasing recognition of infection prevention protocols in oncology care and the continued development of more effective antibiotics are propelling this segment's growth. Furthermore, antibiotic stewardship programs that encourage the judicious use of these medications in neutropenic patients are also gaining traction, enhancing the overall effectiveness of infection management strategies.

Antifungals:

Antifungal medications play a critical role in the management of patients with chemotherapy-induced neutropenia, particularly in preventing and treating fungal infections that can occur due to immune suppression. Drugs like Amphotericin B and Fluconazole are commonly used to provide broad coverage against various fungal pathogens. The increasing prevalence of invasive fungal infections among immunocompromised patients has led to a heightened awareness of the importance of antifungal prophylaxis in these populations. As cancer treatments become more aggressive and the number of patients undergoing chemotherapy rises, the demand for antifungal therapies is expected to grow substantially, thus contributing to the overall market expansion.

Granulocyte Transfusions:

Granulocyte transfusions are a therapeutic option for patients with severe neutropenia and recurrent infections. This treatment involves the infusion of granulocytes from healthy donors to bolster the patient's immune response. Although this approach is not widely adopted due to logistical challenges and limited availability of donor granulocytes, it remains crucial for select patients, especially those with life-threatening infections unresponsive to standard treatments. The growing understanding of the benefits and indications for granulocyte transfusions, coupled with improved donor recruitment strategies, is poised to enhance the viability and acceptance of this treatment option in clinical practice.

Immunoglobulins:

Immunoglobulins, especially intravenous immunoglobulin (IVIG), are utilized in the management of chemotherapy-induced neutropenia, primarily to enhance the immune response in patients suffering from recurrent infections. These products contain pooled immunoglobulin G (IgG) extracted from healthy donors, providing passive immunity against various pathogens. The increasing incidence of infections in neutropenic patients has led to a rise in the usage of immunoglobulins as a supportive therapy. The awareness of their role in improving patient outcomes and the ongoing research exploring their efficacy in various clinical settings are expected to drive growth in this segment of the market.

By Route of Administration

Oral:

The oral route of administration is preferred for its convenience and patient compliance, especially in outpatient settings. Various oral medications, including certain antibiotics and antifungals, are widely utilized in chemotherapy-induced neutropenia management due to their ease of use. Oral therapies allow patients to manage their treatment regimens at home, reducing the need for frequent hospital visits and thereby enhancing their quality of life. As the focus on outpatient cancer care continues to grow, the oral segment is likely to gain momentum, further supported by ongoing innovations in drug formulations that enhance bioavailability and therapeutic effectiveness.

Intravenous:

The intravenous (IV) route of administration is critical for delivering medications to patients with chemotherapy-induced neutropenia, particularly those with severe infections requiring immediate intervention. IV administration ensures rapid delivery of antibiotics, antifungals, and other therapeutic agents directly into the bloodstream, allowing for quick therapeutic effects. This route is particularly advantageous in hospital settings where patients are closely monitored. The growing trend toward aggressive infection management and the increasing complexity of cancer treatments necessitate the use of IV therapies, positioning this segment favorably within the market.

Subcutaneous:

The subcutaneous route of administration has emerged as an important method for delivering certain medications for the treatment of chemotherapy-induced neutropenia, particularly colony-stimulating factors like filgrastim and pegfilgrastim. This method allows for easier administration compared to intravenous methods, enabling patients to receive treatment in a home setting with minimal supervision. The convenience of self-injection and the reduced need for medical personnel significantly enhance patient adherence to treatment regimens. As more patients seek to manage their health conditions at home, the subcutaneous segment is expected to experience sustained growth.

Intramuscular:

Intramuscular administration is a well-established method for delivering specific medications, including certain antibiotics and immunoglobulins, in the context of chemotherapy-induced neutropenia. This route offers the advantage of slower absorption, leading to a prolonged therapeutic effect, which can be beneficial in managing infections. While not as commonly used as other routes, intramuscular injection remains relevant in specific scenarios where rapid and sustained delivery of medication is essential. The ongoing efforts to improve injection techniques and formulations are likely to contribute to the steady demand for intramuscular therapies in this market.

By Drug Class

Filgrastim:

Filgrastim, a recombinant human granulocyte colony-stimulating factor, is extensively used for the prevention and treatment of chemotherapy-induced neutropenia. Its ability to stimulate the bone marrow to produce more neutrophils makes it a frontline agent in managing low white blood cell counts. The increasing incidence of febrile neutropenia in cancer patients undergoing chemotherapy is significantly contributing to the growing acceptance of Filgrastim. Furthermore, the availability of biosimilars has made this treatment option more accessible, leading to a wider adoption across different healthcare settings. With ongoing research establishing its efficacy and safety profiles, Filgrastim is expected to maintain a central role in neutropenia management.

Pegfilgrastim:

Pegfilgrastim is a pegylated form of filgrastim with an extended half-life, which allows for less frequent dosing compared to its non-pegylated counterpart. This characteristic makes pegfilgrastim particularly appealing for patients and healthcare providers alike, as it enhances convenience and adherence to treatment regimens. The growing body of clinical evidence supporting its effectiveness in preventing chemotherapy-induced neutropenia is driving demand for this drug class. With an increasing number of patients undergoing chemotherapy, the utilization of pegfilgrastim is anticipated to rise, further solidifying its position in the market for neutropenia treatment.

Sargramostim:

Sargramostim, a granulocyte-macrophage colony-stimulating factor, is another treatment option for chemotherapy-induced neutropenia. It is particularly used in patients undergoing myeloablative chemotherapy and those with severe neutropenia. Sargramostim promotes the production of both neutrophils and macrophages, providing a broader immune support. Although its use is less common compared to filgrastim and pegfilgrastim, its role remains vital in specific clinical settings. The rising awareness of the need for comprehensive neutropenia management strategies will likely encourage the adoption of sargramostim, especially among hematology-oncology specialists.

Amphotericin B:

Amphotericin B is a key antifungal medication used for treating invasive fungal infections in neutropenic patients. Its broad-spectrum efficacy against a wide range of fungi makes it a critical component of the treatment protocol for patients at high risk for such infections due to chemotherapy-induced immune suppression. Despite its potential for side effects and toxicity, Amphotericin B continues to be a cornerstone in antifungal therapy, particularly in hospitalized patients. The growing incidence of fungal infections among immunocompromised individuals is expected to sustain demand for Amphotericin B, ensuring its place in the chemotherapy-induced neutropenia treatment landscape.

Fluconazole:

Fluconazole, a triazole antifungal agent, is widely used for the prophylaxis and treatment of fungal infections in neutropenic patients. Its oral bioavailability and effectiveness against common fungal pathogens make it a preferred option in outpatient settings. The increasing recognition of the need for antifungal prophylaxis in patients receiving chemotherapy has driven the uptake of fluconazole, particularly among patients who are at moderate risk for fungal infections. Its favorable safety profile and the emergence of generic formulations are anticipated to further enhance its market presence, particularly as part of comprehensive infection management strategies in oncology.

By Indication

Prophylaxis:

Prophylaxis plays a crucial role in the management of chemotherapy-induced neutropenia, focusing primarily on preventing the occurrence of infections before they arise. This proactive approach often involves the use of colony-stimulating factors, antibiotics, and antifungals, tailored to the patient’s risk profile. The increasing recognition of the importance of infection prevention protocols in oncology is driving the demand for prophylactic measures. As healthcare providers aim to improve patient outcomes and minimize hospitalizations associated with fever and infections, the prophylaxis segment is expected to experience significant growth in the coming years. The ongoing research and development of new prophylactic strategies will further bolster this aspect of neutropenia management.

Treatment:

The treatment of chemotherapy-induced neutropenia is crucial for managing the condition once it has developed, and it encompasses a range of interventions aimed at restoring neutrophil levels and preventing complications. Various therapies, including the use of colony-stimulating factors, antibiotics, and antifungals, are essential components of this strategy. The increasing number of patients experiencing chemotherapy-induced neutropenia due to the rising incidence of cancer is expected to drive the demand for treatment options. With advancements in understanding the pathophysiology of neutropenia and the introduction of novel therapies, the treatment segment is poised for substantial growth in the market, facilitating better management of this condition and improving the overall quality of life for affected patients.

By Region

The North American region holds a significant share of the chemotherapy induced neutropenia treatment market, primarily due to the high incidence of cancer and the robust healthcare infrastructure. The region is anticipated to witness continued growth, projected at a CAGR of 6.8% during the forecast period from 2025 to 2035. Factors contributing to this growth include the high adoption rates of advanced therapies, significant investments in cancer research, and the presence of key pharmaceutical companies focused on developing innovative treatment options. Furthermore, increasing awareness among healthcare professionals and patients regarding the management of chemotherapy-related side effects is expected to bolster market expansion.

Europe also represents a substantial market for chemotherapy induced neutropenia treatments, with a growing emphasis on the importance of infection control in cancer care. The European market is characterized by increasing collaborations between healthcare providers and pharmaceutical companies to develop effective treatment protocols. The rise in the elderly population, who are more susceptible to cancer and its complications, further underlines the need for effective neutropenia management. As healthcare systems across Europe continue to emphasize patient-centric care and preventative strategies, the market is expected to see steady growth. The ongoing research initiatives and clinical trials focused on improving treatment outcomes will also support market dynamics in the region.

Opportunities

The chemotherapy induced neutropenia treatment market presents numerous opportunities for growth and development, particularly in the realm of innovative therapies and drug delivery methods. The increasing focus on personalized medicine offers a unique chance to develop tailored treatment approaches that cater to the specific needs of individual patients. This could involve the creation of targeted therapies that minimize side effects while maximizing efficacy. Furthermore, advancements in biologics and biosimilars present significant potential for expansion, as they provide cost-effective alternatives to existing treatments. Companies that successfully navigate this evolving landscape and invest in research and development will likely capture a larger share of the market as patients and healthcare providers seek more effective and personalized treatment solutions.

Another significant opportunity lies in the increasing integration of digital health technologies in oncology care. The rise of telemedicine, remote monitoring, and mobile health applications is transforming how healthcare providers manage chemotherapy-induced neutropenia. By leveraging technology, healthcare professionals can enhance patient engagement and adherence to treatment regimens, ultimately leading to better clinical outcomes. Moreover, the incorporation of artificial intelligence and machine learning in predicting neutropenia risk and optimizing treatment decisions offers unprecedented opportunities for innovation in this space. Companies that harness these technologies to improve patient management and treatment protocols are likely to drive market growth further while enhancing the overall patient experience.

Threats

Despite the promising growth prospects for the chemotherapy induced neutropenia treatment market, several threats could pose challenges to its development. One significant concern is the potential for drug resistance, particularly in antibiotics and antifungals, which may limit the effectiveness of current treatment options. The emergence of multidrug-resistant organisms in neutropenic patients can complicate infection management and lead to poorer clinical outcomes. Moreover, the increasing cost of healthcare and the pressure to reduce expenses may restrict access to advanced therapies and limit the availability of essential medications. Additionally, regulatory hurdles and the lengthy approval processes for new drugs may hinder innovation and slow down market growth. Companies must navigate these challenges carefully to maintain their competitive edge and continue delivering effective treatment solutions.

Another critical threat to the market is the potential for adverse reactions and side effects associated with existing therapies. Patients with chemotherapy-induced neutropenia may experience a range of complications from standard treatments, which can lead to treatment discontinuation or delays. The growing focus on patient safety and outcomes is prompting healthcare providers to seek alternative therapies or strategies, which may impact the demand for traditional treatment options. Additionally, the evolving landscape of cancer treatment, including the rise of immunotherapy and targeted therapies, may shift focus away from conventional neutropenia management strategies. Companies in the market must be vigilant and responsive to these evolving dynamics to ensure continued success.

Competitor Outlook

• Amgen
• Teva Pharmaceutical Industries Ltd.
• Johnson & Johnson
• Roche
• AbbVie Inc.
• Sandoz (a Novartis division)
• Fresenius Kabi
• Mylan N.V.
• Biogen Inc.
• Baxter International Inc.
• GSK (GlaxoSmithKline)
• Hikma Pharmaceuticals
• Celgene Corporation (a Bristol-Myers Squibb Company)
• Gilead Sciences, Inc.
• Sanofi

The competitive landscape of the chemotherapy induced neutropenia treatment market is characterized by a mix of established pharmaceutical companies and emerging players focused on innovation. With a diverse range of treatment options available, companies are striving to differentiate themselves through research and development investments, strategic partnerships, and expanding their product portfolios. The landscape is also marked by collaborations with healthcare providers and academic institutions aimed at enhancing treatment protocols and improving patient outcomes. Moreover, the introduction of biosimilars is creating more competitive pricing dynamics, allowing for broader access to effective therapies, which in turn drives market growth.

Among the major players, Amgen stands out as a leader in the market with its flagship products such as Neupogen (Filgrastim) and Neulasta (Pegfilgrastim), which have significantly transformed the management of chemotherapy-induced neutropenia. The company's ongoing commitment to research and innovation has positioned it well to capitalize on emerging trends and changing patient needs. Similarly, Teva Pharmaceutical Industries Ltd. has made substantial contributions to the market with its portfolio of generic medications and biosimilars, enhancing the accessibility of treatments while maintaining quality standards. Johnson & Johnson also plays a critical role, leveraging its extensive resources and expertise to develop impactful solutions for neutropenia management.

Furthermore, Roche and AbbVie Inc. are notable contenders in this competitive landscape, focusing on developing innovative therapies and ensuring patient safety. Their investments in clinical trials and partnerships with oncology specialists underline their commitment to improving therapeutic outcomes for patients experiencing chemotherapy-induced neutropenia. Sanofi and GSK are also actively engaged in this market, exploring novel treatment avenues and enhancing their existing portfolios to address unmet patient needs. As the market continues to evolve, these companies will need to remain agile and responsive to changes in the competitive landscape, adapting their strategies to maintain their leadership positions while meeting the growing demands of healthcare providers and patients alike.

• 1 Appendix

  • 1.1 List of Tables
  • 1.2 List of Figures

• 2 Introduction

  • 2.1 Market Definition
  • 2.2 Scope of the Report
  • 2.3 Study Assumptions
  • 2.4 Base Currency & Forecast Periods

• 3 Market Dynamics

  • 3.1 Market Growth Factors
  • 3.2 Economic & Global Events
  • 3.3 Innovation Trends
  • 3.4 Supply Chain Analysis

• 4 Consumer Behavior

  • 4.1 Market Trends
  • 4.2 Pricing Analysis
  • 4.3 Buyer Insights

• 5 Key Player Profiles

  • 5.1 Amgen
    • 5.1.1 Business Overview
    • 5.1.2 Products & Services
    • 5.1.3 Financials
    • 5.1.4 Recent Developments
    • 5.1.5 SWOT Analysis
  • 5.2 Roche
    • 5.2.1 Business Overview
    • 5.2.2 Products & Services
    • 5.2.3 Financials
    • 5.2.4 Recent Developments
    • 5.2.5 SWOT Analysis
  • 5.3 Sanofi
    • 5.3.1 Business Overview
    • 5.3.2 Products & Services
    • 5.3.3 Financials
    • 5.3.4 Recent Developments
    • 5.3.5 SWOT Analysis
  • 5.4 Mylan N.V.
    • 5.4.1 Business Overview
    • 5.4.2 Products & Services
    • 5.4.3 Financials
    • 5.4.4 Recent Developments
    • 5.4.5 SWOT Analysis
  • 5.5 AbbVie Inc.
    • 5.5.1 Business Overview
    • 5.5.2 Products & Services
    • 5.5.3 Financials
    • 5.5.4 Recent Developments
    • 5.5.5 SWOT Analysis
  • 5.6 Biogen Inc.
    • 5.6.1 Business Overview
    • 5.6.2 Products & Services
    • 5.6.3 Financials
    • 5.6.4 Recent Developments
    • 5.6.5 SWOT Analysis
  • 5.7 Fresenius Kabi
    • 5.7.1 Business Overview
    • 5.7.2 Products & Services
    • 5.7.3 Financials
    • 5.7.4 Recent Developments
    • 5.7.5 SWOT Analysis
  • 5.8 Johnson & Johnson
    • 5.8.1 Business Overview
    • 5.8.2 Products & Services
    • 5.8.3 Financials
    • 5.8.4 Recent Developments
    • 5.8.5 SWOT Analysis
  • 5.9 GSK (GlaxoSmithKline)
    • 5.9.1 Business Overview
    • 5.9.2 Products & Services
    • 5.9.3 Financials
    • 5.9.4 Recent Developments
    • 5.9.5 SWOT Analysis
  • 5.10 Gilead Sciences, Inc.
    • 5.10.1 Business Overview
    • 5.10.2 Products & Services
    • 5.10.3 Financials
    • 5.10.4 Recent Developments
    • 5.10.5 SWOT Analysis
  • 5.11 Hikma Pharmaceuticals
    • 5.11.1 Business Overview
    • 5.11.2 Products & Services
    • 5.11.3 Financials
    • 5.11.4 Recent Developments
    • 5.11.5 SWOT Analysis
  • 5.12 Baxter International Inc.
    • 5.12.1 Business Overview
    • 5.12.2 Products & Services
    • 5.12.3 Financials
    • 5.12.4 Recent Developments
    • 5.12.5 SWOT Analysis
  • 5.13 Sandoz (a Novartis division)
    • 5.13.1 Business Overview
    • 5.13.2 Products & Services
    • 5.13.3 Financials
    • 5.13.4 Recent Developments
    • 5.13.5 SWOT Analysis
  • 5.14 Teva Pharmaceutical Industries Ltd.
    • 5.14.1 Business Overview
    • 5.14.2 Products & Services
    • 5.14.3 Financials
    • 5.14.4 Recent Developments
    • 5.14.5 SWOT Analysis
  • 5.15 Celgene Corporation (a Bristol-Myers Squibb Company)
    • 5.15.1 Business Overview
    • 5.15.2 Products & Services
    • 5.15.3 Financials
    • 5.15.4 Recent Developments
    • 5.15.5 SWOT Analysis

• 6 Market Segmentation

  • 6.1 Chemotherapy Induced Neutropenia Treatment Market, By Drug Class
    • 6.1.1 Filgrastim
    • 6.1.2 Pegfilgrastim
    • 6.1.3 Sargramostim
    • 6.1.4 Amphotericin B
    • 6.1.5 Fluconazole
  • 6.2 Chemotherapy Induced Neutropenia Treatment Market, By Indication
    • 6.2.1 Prophylaxis
    • 6.2.2 Treatment
  • 6.3 Chemotherapy Induced Neutropenia Treatment Market, By Treatment Type
    • 6.3.1 Colony-Stimulating Factors
    • 6.3.2 Antibiotics
    • 6.3.3 Antifungals
    • 6.3.4 Granulocyte Transfusions
    • 6.3.5 Immunoglobulins
  • 6.4 Chemotherapy Induced Neutropenia Treatment Market, By Route of Administration
    • 6.4.1 Oral
    • 6.4.2 Intravenous
    • 6.4.3 Subcutaneous
    • 6.4.4 Intramuscular

• 7 Competitive Analysis

  • 7.1 Key Player Comparison
  • 7.2 Market Share Analysis
  • 7.3 Investment Trends
  • 7.4 SWOT Analysis

• 8 Research Methodology

  • 8.1 Analysis Design
  • 8.2 Research Phases
  • 8.3 Study Timeline

• 9 Future Market Outlook

  • 9.1 Growth Forecast
  • 9.2 Market Evolution

• 10 Geographical Overview

  • 10.1 Europe - Market Analysis
    • 10.1.1 By Country
      • 10.1.1.1 UK
      • 10.1.1.2 France
      • 10.1.1.3 Germany
      • 10.1.1.4 Spain
      • 10.1.1.5 Italy
  • 10.2 Asia Pacific - Market Analysis
    • 10.2.1 By Country
      • 10.2.1.1 India
      • 10.2.1.2 China
      • 10.2.1.3 Japan
      • 10.2.1.4 South Korea
  • 10.3 Latin America - Market Analysis
    • 10.3.1 By Country
      • 10.3.1.1 Brazil
      • 10.3.1.2 Argentina
      • 10.3.1.3 Mexico
  • 10.4 North America - Market Analysis
    • 10.4.1 By Country
      • 10.4.1.1 USA
      • 10.4.1.2 Canada
  • 10.5 Middle East & Africa - Market Analysis
    • 10.5.1 By Country
      • 10.5.1.1 Middle East
      • 10.5.1.2 Africa
  • 10.6 Chemotherapy Induced Neutropenia Treatment Market by Region

• 11 Global Economic Factors

  • 11.1 Inflation Impact
  • 11.2 Trade Policies

• 12 Technology & Innovation

  • 12.1 Emerging Technologies
  • 12.2 AI & Digital Trends
  • 12.3 Patent Research

• 13 Investment & Market Growth

  • 13.1 Funding Trends
  • 13.2 Future Market Projections

• 14 Market Overview & Key Insights

  • 14.1 Executive Summary
  • 14.2 Key Trends
  • 14.3 Market Challenges
  • 14.4 Regulatory Landscape

Segments Analyzed in the Report

The global Chemotherapy Induced Neutropenia Treatment market is categorized based on

By Treatment Type

• Colony-Stimulating Factors
• Antibiotics
• Antifungals
• Granulocyte Transfusions
• Immunoglobulins

By Route of Administration

• Oral
• Intravenous
• Subcutaneous
• Intramuscular

By Drug Class

• Filgrastim
• Pegfilgrastim
• Sargramostim
• Amphotericin B
• Fluconazole

By Indication

• Prophylaxis
• Treatment

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Players

• Amgen
• Teva Pharmaceutical Industries Ltd.
• Johnson & Johnson
• Roche
• AbbVie Inc.
• Sandoz (a Novartis division)
• Fresenius Kabi
• Mylan N.V.
• Biogen Inc.
• Baxter International Inc.
• GSK (GlaxoSmithKline)
• Hikma Pharmaceuticals
• Celgene Corporation (a Bristol-Myers Squibb Company)
• Gilead Sciences, Inc.
• Sanofi